A detailed history of Dimensional Fund Advisors LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 327,080 shares of VRDN stock, worth $6.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
327,080
Previous 107,580 204.03%
Holding current value
$6.59 Million
Previous $1.4 Million 431.88%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$12.16 - $23.33 $2.67 Million - $5.12 Million
219,500 Added 204.03%
327,080 $7.44 Million
Q2 2024

Aug 09, 2024

BUY
$11.6 - $17.26 $1.13 Million - $1.68 Million
97,510 Added 968.32%
107,580 $1.4 Million
Q2 2023

Aug 09, 2023

SELL
$22.57 - $29.67 $19,319 - $25,397
-856 Reduced 7.83%
10,070 $239,000
Q1 2023

May 12, 2023

SELL
$25.04 - $37.6 $11,818 - $17,747
-472 Reduced 4.14%
10,926 $277,000
Q2 2022

Aug 12, 2022

BUY
$9.55 - $19.0 $108,850 - $216,562
11,398 New
11,398 $132,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $803M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.